REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03777254
- Locations
- 🇨🇳
Beijing Tongren Hospital .Cmu, Beijing, China
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 127
- Registration Number
- NCT03556345
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT03507166
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, N/A = Not Applicable, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, N/A = Not Applicable, China
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT03500380
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT03330418
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT03052634
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The first bethune hospital of jilin unversity, Changchun, Jilin, China
🇨🇳Liaoning cancer hospital & institute, Shenyang, Liaoning, China
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT03016013
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 249
- Registration Number
- NCT02885610
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02882087
- Locations
- 🇨🇳
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02881138
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China